HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Epigenetic regulation in atherosclerosis: reversible changes as a therapeutic target

Louis Nervegna · Aug 25, 2026 · ♥ 4 reactions · 1 comments · original Facebook post
Plaque, CAC & CT angiographyAging & longevity
AI summary & key facts

Louis shares a 2026 Nature Reviews Cardiology review on how epigenetic modifications guide gene programs in endothelial, smooth muscle and immune cells in atherosclerosis. He notes epigenetic age can be reversed in cells and to a limited degree in animals, but it is still early.

We now have the ability to reverse the epigenetic age of cells in vitro, and also to a limited degree in animal experiments.

There is even a small human trial testing the technology in advanced glaucoma: ↪ First epigenetic reprogramming trial in the eye; cardiovascular use is speculative.

This work is still in its infancy, but it may one day revolutionize cardiology.

Link to journal article:

Paper · Nat Rev Cardiol · 2026Epigenetic regulation in atherosclerosis and its therapeutic potentialnature.com

Quoted:

“In this Review, we provide an overview of epigenetic regulation in atherosclerosis, focusing on how these dynamic, reversible modifications orchestrate gene expression in vascular endothelial cells, vascular smooth muscle cells and immune cells. We highlight how technological advances and the integration of multimodal datasets have progressed this research field and describe the cell-specific contributions of genetically associated loci. Finally, we discuss preclinical study findings and the translational efforts towards the development of epigenetic drugs as promising interventions to attenuate atherosclerotic plaque progression and inflammation, shedding light on the challenges of specificity, delivery and long-term safety. Achieving clinical applicability will enable precision medicine approaches to transform atherosclerosis therapy.”

“Epigenetics can be used in the clinic for prognostic applications, including DNA methylation-based scores and epigenetic clocks; moreover, targeting epigenetic enzymes and regulatory pathways offers options for improved tailored therapy in cardiology.”

#epigeneticsHD #epigeneticclockHD #agingHD #longevityHD #cvdHD #epigeneticreprogrammingHD

Research cited

Nature Reviews Cardiology: In this Review, the authors provide an overview of epigenetic regulation in atherosclerosis, focusing on how epigenetic modifications guide cell-specific transcriptional programmes in vascular endothelial cells, vascular smooth muscle cells, and immune cells to regulate cell plasticity and intercellular communication. They also discuss translational opportunities and the challenges of using epigenetic drugs to treat atherosclerotic cardiovascular disease.

Link to the Review in the comments.

Diagram details hyperlipidaemia & aging contributing to atherosclerosis. (a) Trained immunity leads to IL-1β-releasing macrophages. (b) CHIP (TET2/DNMT3A-deficient HSCs) causes inflammatory macrophages. (c) T cell polarization and repression reduce anti-inflammatory cells/cytokines. All paths lead to atherosclerosis.
← newer: Case report: severe LAD blockage became mild after 4 years oolder: 100 mg vitamin B6 reduced depression symptoms in a new rando →